OOIR: Observatory of International Research

Papers

(The H4-Index of mAbs is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Antibodies to watch in 2022	263
Antibodies to watch in 2021	249
Antibodies to watch in 2023	156
Targeting cancer with antibody-drug conjugates: Promises and challenges	102
BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning	81
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy	67
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies	66
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	51
Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics	51
In silico proof of principle of machine learning-based antibody design at unconstrained scale	50
Developments and opportunities in continuous biopharmaceutical manufacturing	50
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro	49
Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns	45
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins	45
Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics	43
Coming together at the hinges: Therapeutic prospects of IgG3	40
Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods	39
Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation	38
Antibodies to watch in 2024	36
Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies	36
Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries	35
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors	35
Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development	34
Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parameters	34
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics	33

Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies	33
A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-pertussis toxoid antibodies	33
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy	31
Assessing developability early in the discovery process for novel biologics	30
Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics	29
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	29
Impact of IgG subclass on molecular properties of monoclonal antibodies	29
Harnessing the potential of machine learning for advancing “Quality by Design” in biomanufacturing	29